Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib|
|Citation:||Clinical Pharmacology & Therapeutics, 2014; 95(3):294-306|
|L N Eadie, T P Hughes and D L White|
|Abstract:||The efflux transporters adenosine triphosphate (ATP)-binding cassette (ABC)B1 and ABCG2 have been demonstrated to interact with the tyrosine kinase inhibitors (TKIs) imatinib, nilotinib, and dasatinib. However, although some studies conclude that TKIs are substrates of one or both transporters, other studies demonstrate only an inhibitory function. This variation is probably due to differences in the concentration of TKIs assayed and the experimental systems used. This article examines the evidence for clinically relevant interactions between three currently approved TKIs and ABCB1/ABCG2.|
|Keywords:||Animals; Humans; Benzamides; Piperazines; Pyrimidines; Thiazoles; ATP-Binding Cassette Transporters; Neoplasm Proteins; Enzyme Inhibitors; Protein-Tyrosine Kinases; Imatinib Mesylate; Dasatinib; ATP Binding Cassette Transporter, Sub-Family G, Member 2; ATP Binding Cassette Transporter, Sub-Family B; ATP-Binding Cassette, Sub-Family B, Member 1|
|Rights:||© 2014 American Society for Clinical Pharmacology and Therapeutics|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.